A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Montefiore Medical Center
SWOG Cancer Research Network
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
Nammi Therapeutics Inc
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Revolution Medicines, Inc.
AstraZeneca
Memorial Sloan Kettering Cancer Center
Conjupro Biotherapeutics, Inc.
Avera McKennan Hospital & University Health Center
Whitehawk Therapeutics, Inc.
City of Hope Medical Center
National Cancer Institute (NCI)
SystImmune Inc.
M.D. Anderson Cancer Center
Institut Paoli-Calmettes
Wake Forest University Health Sciences
Filamon LTD
Eli Lilly and Company
On Target Laboratories, LLC
PMV Pharmaceuticals, Inc
Mayo Clinic
Convalife (Shanghai) Co., Ltd.
University of California, Irvine
ViroMissile, Inc.
Sichuan Enray Pharmaceutical Sciences Company
Carevive Systems, Inc.
A2 Biotherapeutics Inc.
Tizona Therapeutics, Inc
Essen Biotech
National Institutes of Health Clinical Center (CC)
Clasp Therapeutics, Inc.
New Phase Ltd.
Revolution Medicines, Inc.
University of Colorado, Denver
National Cancer Institute (NCI)
Institut Bergonié
Royal Marsden NHS Foundation Trust
SystImmune Inc.
Pheon Therapeutics
Daiichi Sankyo
Grey Wolf Therapeutics
University of Nebraska